| Estrogen biosynthesis and action in ovarian cancer F Mungenast, T Thalhammer Frontiers in endocrinology 5, 192, 2014 | 167 | 2014 |
| Future aspects for cannabinoids in breast cancer therapy T Kisková, F Mungenast, M Suváková, W Jäger, T Thalhammer International journal of molecular sciences 20 (7), 1673, 2019 | 147 | 2019 |
| AllergoOncology–the impact of allergy in oncology: EAACI position paper E Jensen‐Jarolim, HJ Bax, R Bianchini, M Capron, C Corrigan, M Castells, ... Allergy 72 (6), 866-887, 2017 | 96 | 2017 |
| Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance L Klameth, B Rath, M Hochmaier, D Moser, M Redl, F Mungenast, ... Scientific reports 7 (1), 5337, 2017 | 90 | 2017 |
| Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer F Mungenast, S Aust, I Vergote, A Vanderstichele, J Sehouli, E Braicu, ... Oncology Letters 13 (6), 4047-4054, 2017 | 38 | 2017 |
| Next-generation digital histopathology of the tumor microenvironment F Mungenast, A Fernando, R Nica, B Boghiu, B Lungu, J Batra, RC Ecker Genes 12 (4), 538, 2021 | 29 | 2021 |
| Exploring the role of sphingolipid machinery during the epithelial to mesenchymal transition program using an integrative approach A Meshcheryakova, M Svoboda, A Tahir, HC Koefeler, A Triebl, ... Oncotarget 7 (16), 22295, 2016 | 26 | 2016 |
| Interrelations of sphingolipid and lysophosphatidate signaling with immune system in ovarian cancer A Meshcheryakova, M Svoboda, M Jaritz, F Mungenast, M Salzmann, ... Computational and Structural Biotechnology Journal 17, 537-560, 2019 | 22 | 2019 |
| The immune phenotype of isolated lymphoid structures in non-tumorous colon mucosa encrypts the information on pathobiology of metastatic colorectal cancer F Mungenast, A Meshcheryakova, A Beer, M Salzmann, D Tamandl, ... Cancers 12 (11), 3117, 2020 | 12 | 2020 |
| Clinical significance of organic anion transporting polypeptide gene expression in high-grade serous ovarian cancer M Svoboda, F Mungenast, A Gleiss, I Vergote, A Vanderstichele, ... Frontiers in pharmacology 9, 842, 2018 | 11 | 2018 |
| Tissue image cytometry A Meshcheryakova, F Mungenast, R Ecker, D Mechtcheriakova Imaging Modalities for Biological and Preclinical Research: A Compendium …, 2021 | 7 | 2021 |
| An integrative MuSiCO algorithm: from the patient-specific transcriptional profiles to novel checkpoints in disease pathobiology A Meshcheryakova, P Zimmermann, R Ecker, F Mungenast, G Heinze, ... Systems Biology, 351-372, 2018 | 7 | 2018 |
| Interplay between partial EMT and cisplatin resistance as the drivers for recurrence in HNSCC J Ingruber, J Dudas, S Sprung, B Lungu, F Mungenast Biomedicines 10 (10), 2482, 2022 | 6 | 2022 |
| Systems Biology A Meshcheryakova, P Zimmermann, R Ecker, F Mungenast, G Heinze, ... Springer, 2018 | 5 | 2018 |
| SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer S Koller, J Kendler, J Karacs, A Wolf, C Kreuzinger, I Von Der Decken, ... Frontiers in Pharmacology 13, 946348, 2022 | 3 | 2022 |
| Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC. Biomedicines 2022, 10, 2482 J Ingruber, J Dudas, S Sprung, B Lungu, F Mungenast Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell …, 2022 | | 2022 |
| Next-Generation Digital Histopathology of the Tumor Microenvironment. Genes 2021, 12, 538 F Mungenast, A Fernando, R Nica, B Boghiu, B Lungu, J Batra, RC Ecker s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Sphingolipid machinery in EMT: From a cell-based model to pathobiology of lung cancer A Meshcheryakova, M Svoboda, HC Koefeler, A Triebl, F Mungenast, ... International Journal of Molecular Medicine 36, S43-S43, 2015 | | 2015 |
| 166 Understanding the heterogeneity of B-cell subsets: From classical germinal centers to ectopic follicles at tumor site F Mungenast, A Meshcheryakova, A Oswald, E Bajna, D Tamandl, ... European Journal of Cancer 3 (51), S19, 2015 | | 2015 |
| Estrogen-inactivating sulfotransferase has benefical effects in advanced serous ovarian cancer F Mungenast, S Aust, K Ocko, L Klameth, CD Castilo-Tong, R Zeillinger, ... Oncology Research And Treatment 37, 266-266, 2014 | | 2014 |
